Sobrevida a mediano plazo en los pacientes con hipertensión arterial pulmonar en la era de terapias vasodilatadoras específicas del territorio vascular pulmonar

SURVIVAL OF PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION AFTER THE ADVENT OF SPECIFIC PULMONARY VASODILATOR THERAPIES

Author
Herrera, Sebastian; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Gabrielli, Luigi; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Paredes, Alejandro; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Saavedra, Rodrigo; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Ocaranza, María Paz; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Sepúlveda, Pablo; División de Cardiología Hospital San Juan de Dios

Donoso, Hernán; División de Cardiología Hospital San Juan de Dios

López, Leonel; División de Cardiología Hospital San Juan de Dios

Verdejo, Hugo; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Baraona, Fernando; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Castro, Pablo; División de Enfermedades Cardiovasculares Pontificia Universidad Católica de Chile

Full text
http://www.revistamedicadechile.cl/ojs/index.php/rmedica/article/view/4623
Abstract
Background: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Long-term survival remains poor despite of advances in specific vasodilator therapy. Aim: To describe the survival rate in a cohort of PAH patients in two referral centers in Chile. Patients and methods: One hundred fifteen patients aged 43 ± 15.6 years (85 % females) with PAH qualified for this study. Their median pulmonary artery pressure was 55.4 ±14 mm Hg and their six minutes walking capacity was 368 ± 119 m. They were followed for 58 ± 0.4 months and their actual survival rates were compared with the estimated survival using the equation proposed by the French registry of PAH. Results: One, two and three year survival rates were 97, 94 and 89%, respectively. The observed survival rates were greater than the estimated survival. Conclusions: The improvement in survival rates observed in this cohort of patients is similar to what has been described in literature.
 
Background: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Long-term survival remains poor despite of advances in specific vasodilator therapy. Aim: To describe the survival rate in a cohort of PAH patients in two referral centers in Chile. Patients and methods: One hundred fifteen patients aged 43 ± 15.6 years (85 % females) with PAH qualified for this study. Their median pulmonary artery pressure was 55.4 ±14 mm Hg and their six minutes walking capacity was 368 ± 119 m. They were followed for 58 ± 0.4 months and their actual survival rates were compared with the estimated survival using the equation proposed by the French registry of PAH. Results: One, two and three year survival rates were 97, 94 and 89%, respectively. The observed survival rates were greater than the estimated survival. Conclusions: The improvement in survival rates observed in this cohort of patients is similar to what has been described in literature.
 
Metadata
Show full item record